Enter your email address
Submit
Write your message
Volume 19, Issue 1 (Iranian Journal of Breast Diseases 2027)
ijbd 2027, 19(1): 77-91 |
Back to browse issues page
Ethics code: IR.SBMU.PHARMACY.REC.1402.182
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Karami Zarandi F, Hajian S, Mirzaei H R, Khabazkhoob M. Comparison of the Quality of Life in Women with Breast Cancer Under Different Adjuvant Hormone Therapy Regimens: A Cross-Sectional Study. ijbd 2027; 19 (1) :77-91
URL: http://ijbd.ir/article-1-1206-en.html
URL: http://ijbd.ir/article-1-1206-en.html
1- Student Research Committee, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Department of Midwifery, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. (Corresponding Author) ,s.hajian@sbmu.ac.ir
3- Cancer Research Center, Shohadae Tajrish Hospital, Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4- Department of Medical Surgical Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Department of Midwifery, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. (Corresponding Author) ,
3- Cancer Research Center, Shohadae Tajrish Hospital, Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4- Department of Medical Surgical Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract: (85 Views)
Introduction: Adjuvant hormonal therapy (AHT) lowers recurrence in hormone receptor–positive breast cancer, but evidence comparing its impact on quality of life (QoL) across menopausal status is limited. This study aimed to compare QoL across different AHT regimens in premenopausal and postmenopausal women with breast cancer.
Methods: In this cross-sectional study, 229 women with early breast cancer (133 premenopausal and 96 postmenopausal) were selected using a census sampling method. Premenopausal patients were assigned to three groups: tamoxifen (TAM), tamoxifen plus a gonadotropin-releasing hormone agonist (TAM + GnRH), or an aromatase inhibitor plus a gonadotropin-releasing hormone agonist (AI + GnRH). Postmenopausal patients were assigned to two groups: one receiving TAM and the other receiving an AI. Data were collected using the EORTC QLQ-BR45, a validated and specific tool for assessing quality of life in women with breast cancer. Data were analyzed using SPSS software version 27.0.
Results: Premenopausal women treated with TAM had better sexual functioning than those receiving AI+GnRH (P <0.001) or TAM+GnRH (P=0.003). Premenopausal women treated with AI+GnRH had more systemic therapy side effects (P=0.005), upset by hair loss (P=0.022), and Endocrine Sexual (P=0.023) than patients treated with TAM. In postmenopausal women, no significant difference was observed between the TAM and AI groups on any of the symptom or functional scales evaluated (N.S.).
Conclusion: Adjuvant AI+GnRH therapy in premenopausal women was linked to increased hair loss and sexual dysfunction compared to TAM. In postmenopausal patients, no significant quality-of-life differences emerged between TAM and AI treatments. These findings suggest potential differences in tolerability that may guide therapy choices, particularly for premenopausal women.
Methods: In this cross-sectional study, 229 women with early breast cancer (133 premenopausal and 96 postmenopausal) were selected using a census sampling method. Premenopausal patients were assigned to three groups: tamoxifen (TAM), tamoxifen plus a gonadotropin-releasing hormone agonist (TAM + GnRH), or an aromatase inhibitor plus a gonadotropin-releasing hormone agonist (AI + GnRH). Postmenopausal patients were assigned to two groups: one receiving TAM and the other receiving an AI. Data were collected using the EORTC QLQ-BR45, a validated and specific tool for assessing quality of life in women with breast cancer. Data were analyzed using SPSS software version 27.0.
Results: Premenopausal women treated with TAM had better sexual functioning than those receiving AI+GnRH (P <0.001) or TAM+GnRH (P=0.003). Premenopausal women treated with AI+GnRH had more systemic therapy side effects (P=0.005), upset by hair loss (P=0.022), and Endocrine Sexual (P=0.023) than patients treated with TAM. In postmenopausal women, no significant difference was observed between the TAM and AI groups on any of the symptom or functional scales evaluated (N.S.).
Conclusion: Adjuvant AI+GnRH therapy in premenopausal women was linked to increased hair loss and sexual dysfunction compared to TAM. In postmenopausal patients, no significant quality-of-life differences emerged between TAM and AI treatments. These findings suggest potential differences in tolerability that may guide therapy choices, particularly for premenopausal women.
Type of Study: Research |
Subject:
Diagnosis, treatment, rehabilitation
Received: 2025/09/17 | Accepted: 2026/02/25 | Published: 2026/03/25
Received: 2025/09/17 | Accepted: 2026/02/25 | Published: 2026/03/25
References
1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2024;74(3):229-63. [DOI:10.3322/caac.21834] [PMID]
2. Sha R, Kong X-m, Li X-y, Wang Y-b. Global burden of breast cancer and attributable risk factors in 204 countries and territories, from 1990 to 2021: results from the Global Burden of Disease Study 2021. Biomarker Research. 2024;12(1):87. [DOI:10.1186/s40364-024-00631-8] [PMID] []
3. Kazeminia M, Salari N, Hosseinian-Far A, Akbari H, Bazrafshan M-R, Mohammadi M.
4. The prevalence of breast cancer in Iranian women: a systematic review and meta-analysis. Indian Journal of Gynecologic Oncology. 2022;20(1):14. [DOI:10.1007/s40944-022-00613-4]
5. Zahedi A, Rafiemanesh H, Enayatrad M, Ghoncheh M, Salehiniya H. Incidence, trends, and epidemiology of cancers in north west of Iran. Asian Pacific Journal of Cancer Prevention. 2015;16(16):7189-93. [DOI:10.7314/APJCP.2015.16.16.7189] [PMID]
6. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast. 2022;66:15-23. [DOI:10.1016/j.breast.2022.08.010] [PMID] []
7. Cavazza M, Banks H, Ercolanoni M, Cukaj G, Bianchi G, Capri G, et al. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management. Breast cancer research and treatment. 2020;183:189-99. [DOI:10.1007/s10549-020-05748-6] [PMID]
8. Rosso R, D'Alonzo M, Bounous VE, Actis S, Cipullo I, Salerno E, et al. Adherence to adjuvant endocrine therapy in breast cancer patients. Current Oncology. 2023;30(2):1461-72. [DOI:10.3390/curroncol30020112] [PMID] []
9. Font R, Espinas JA, Barnadas A, Izquierdo A, Galceran J, Saladie F, et al. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain. Breast cancer research and treatment. 2019;175:733-40. [DOI:10.1007/s10549-019-05201-3] [PMID]
10. Peddie N, Agnew S, Crawford M, Dixon D, MacPherson I, Fleming L. The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a qualitative systematic review and thematic synthesis. The Breast. 2021;58:147-59. [DOI:10.1016/j.breast.2021.05.005] [PMID] []
11. Sitlinger A, Zafar SY. Health-related quality of life: the impact on morbidity and mortality. Surgical oncology clinics of North America. 2018;27(4):675. [DOI:10.1016/j.soc.2018.05.008] [PMID] []
12. Paunescu A-C, Préau M, Delpierre C, Jacob G, Pannard M, Delrieu L, et al. Quality of life among French breast cancer survivors in comparison with cancer-free women: the Seintinelles study. BMC women's health. 2024;24(1):17. [DOI:10.1186/s12905-023-02827-w] [PMID] []
13. Dedic Plavetic N, Dugonjic Okrosa A, Silovski T, Jovic Zlatovic J, Jajac Brucic L, Skelin M, et al. Influence of ovarian function suppression on quality of life in breast cancer survivors during adjuvant endocrine therapy-American Society of Clinical Oncology; 2023. [DOI:10.1200/JCO.2023.41.16_suppl.560]
14. Van Nes J, Voskuil D, van Leeuwen F, Junggeburt J, de Haes H, van de Velde C. Quality of life in relation to hormonal treatment of postmenopausal women in the Dutch Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Cancer Research. 2009;69(2_Supplement):21. [DOI:10.1158/0008-5472.SABCS-21]
15. Kilickap S, Hayran M, Cakir B, Cilingiroglu N, Erman M, Buyukdamgaci G, et al. Effect of endocrine therapy on quality of life and cognitive functions in patients with breast cancer. Breast care. 2013;8(2):128-32. [DOI:10.1159/000350780] [PMID] []
16. Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, Da Costa R, et al. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Annals of Oncology. 2020;31(2):283-8. [DOI:10.1016/j.annonc.2019.10.027] [PMID]
17. Getu MA, Chen C, Wang P, Kantelhardt EJ, Addissie A. Quality of life and its influencing factors among breast cancer patients at Tikur Anbessa specialised hospital, Addis Ababa, Ethiopia. BMC cancer. 2022;22(1):897. [DOI:10.1186/s12885-022-09921-6] [PMID] []
18. Montazeri A, Harirchi I, Vahdani M, Khaleghi F, Jarvandi S, Ebrahimi M, et al. The EORTC breast cancer-specific quality of life questionnaire (EORTC QLQ-BR23): translation and validation study of the Iranian version. Quality of Life Research. 2000;9:177-84. [DOI:10.1023/A:1008918310251] [PMID]
19. Omidi Z, Farajivafa V, Ansari M, Bagheri A, Sajadian A, Foudazi H, et al. Exploratory and confirmatory factor analysis of the Persian Version of the European Organization for Research and Treatment of Cancer Quality of Life-Breast Cancer questionnaires with 45 and 42 items: EORTC QLQ-BR45 and QLQ-BR42. Iranian Journal of Breast Diseases. 2025;17(4):32-51. [DOI:10.61186/ijbd.17.4.32]
20. Kiliç S. Analysis of covariance. Psychiatry and Behavioral Sciences. 2017;7(1):73.
21. Ribi K, Luo W, Bernhard J, Francis PA, Bellet M, Burstein HJ, et al. Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression [DOI:10.1158/1538-7445.SABCS14-S3-09]
22. (OFS) in premenopausal women with hormone receptor-positive tumors. Cancer Research. 2015;75(9_Supplement):S3-09-S3-. [DOI:10.1158/1538-7445.SABCS14-S3-09]
23. Gallicchio L, Calhoun C, Helzlsouer KJ. Aromatase inhibitor therapy and hair loss among breast cancer survivors. Breast cancer research and treatment. 2013;142(2):435-43. [DOI:10.1007/s10549-013-2744-2] [PMID]
24. Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. The Lancet Oncology. 2015;16(7):848-58. [DOI:10.1016/S1470-2045(15)00049-2] [PMID] []
25. Xiao H, Jiang X, Chen C, Montero AJ, Diaby V. Longitudinal effects of adjuvant endocrine therapy on the quality of life of post-menopausal women with non-metastatic ER+ breast cancer: a systematic review. PharmacoEconomics-Open. 2018;2(4):359-69. [DOI:10.1007/s41669-018-0070-7] [PMID] []
26. Lambertini M, Arecco L, Woodard TL, Messelt A, Rojas KE. Advances in the management of menopausal symptoms, fertility preservation, and bone health for women with breast cancer on endocrine therapy. American Society of Clinical Oncology Educational Book. 2023;43:e390442. [DOI:10.1200/EDBK_390442] [PMID]
27. Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, et al. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT. Journal of clinical oncology. 2020;38(12):1293-303. [DOI:10.1200/JCO.18.01967] [PMID] []
28. Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. Journal of Clinical Oncology. 2023;41(7):1376-82. [DOI:10.1200/JCO.22.01064] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
